Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent <i>Plasmodium falciparum</i> malaria transmission in Ouelessebougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial.

ABSTRACT:

Background

Pyronaridine-artesunate is the most recently licensed artemisinin-based combination therapy. WHO has recommended that a single low dose of primaquine could be added to artemisinin-based combination therapies to reduce Plasmodium falciparum transmission in areas aiming for elimination of malaria or areas facing artemisinin resistance. We aimed to determine the efficacy of pyronaridine-artesunate and dihydroartemisinin-piperaquine with and without single low-dose primaquine for reducing gametocyte density and transmission to mosquitoes.

Methods

We conducted a four-arm, single-blind, phase 2/3, randomised trial at the Ouélessébougou Clinical Research Unit of the Malaria Research and Training Centre of the University of Bamako (Bamako, Mali). Participants were

SUBMITTER: Stone W 

PROVIDER: S-EPMC8721154 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature